Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study by White, Clare. et al.
www.thelancet.com/haematology   Vol 6   February 2019 e79
Articles
Prevalence, symptom burden, and natural history of deep 
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Summary
Background The prevalence of deep venous thrombosis in patients with advanced cancer is unconfirmed and it is 
unknown whether current international thromboprophylaxis guidance is applicable to this population. We aimed to 
determine prevalence and predictors of femoral deep vein thrombosis in patients admitted to specialist palliative care 
units (SPCUs).
Methods We did this prospective longitudinal observational study in five SPCUs in England, Wales, and Northern 
Ireland (four hospices and one palliative care unit). Consecutive adults with cancer underwent bilateral femoral vein 
ultrasonography on admission and weekly until death or discharge for a maximum of 3 weeks. Data were collected on 
performance status, attributable symptoms, and variables known to be associated with venous thromboembolism. 
Patients with a short estimated prognosis (<5 days) were ineligible. The primary endpoint of the study was the 
prevalence of femoral deep vein thrombosis within 48 h of SPCU admission, analysed by intention to treat. This 
study is registered with the ISRCTN registry, number ISRCTN97567719.
Findings Between June 20, 2016, and Oct 16, 2017, 343 participants were enrolled (mean age 68·2 years [SD 12·8; 
range 25–102]; 179 [52%] male; mean Australian-modified Karnofsky performance status 49 [SD 16·6; range 20–90]). 
Of 273 patients with evaluable scans, 92 (34%, 95% CI 28–40) had femoral deep vein thrombosis. Four participants 
with a scan showing no deep vein thrombosis on admission developed a deep vein thrombosis on repeat scanning 
over 21 days. Previous venous thromboembolism (p=0·014), being bedbound in the past 12 weeks for any reason 
(p=0·003), and lower limb oedema (p=0·009) independently predicted deep vein thrombosis. Serum albumin 
concentration (p=0·43), thromboprophylaxis (p=0·17), and survival (p=0·45) were unrelated to deep vein thrombosis.
Interpretation About a third of patients with advanced cancer admitted to SPCUs had a femoral deep vein thrombosis. 
Deep vein thrombosis was not associated with thromboprophylaxis, survival, or symptoms other than leg oedema. 
These findings are consistent with venous thromboembolism being a manifestation of advanced disease rather than 
a cause of premature death. Thromboprophylaxis for SPCU inpatients with poor performance status seems to be of 
little benefit.
Funding National Institute for Health Research (Research for Patient Benefit programme).
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Venous thromboembolism (deep venous thrombosis and 
pulmonary embolism) is the most common preventable 
cause of hospital death.1 Prevention of hospital-acquired 
thrombosis is a major health service focus and ranks as 
the number one hospital strategy for patient safety 
improvement worldwide.2 People with cancer are at 
particular risk of venous thromboembolism and clinical 
guidelines recommend pharmacological thrombo- 
prophylaxis for all patients with cancer if hospitalised 
with acute illness.3,4 The presence of cancer is an 
independent risk factor for venous thromboembolism 
that varies according to primary tumour, stage, 
and associated cancer-modifying treatments. However, 
guideline recommendations are extrapolated from 
thromboprophylaxis trials not done specifically in cancer 
cohorts and do not consider varying thrombogenicity 
across the cancer population, particularly as the cancer 
progresses.5 Patients with advanced cancer and a life 
expectancy of less than 3 months were also excluded 
systematically from these studies.
Most people with advanced, incurable cancer will be 
admitted to hospital where they will receive thrombo- 
prophylaxis routinely.6 Only a small proportion will be 
admitted to a specialist palliative care unit (SPCU), where 
thromboprophylaxis is a matter of debate, the primary 
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focus of palliative care being symptom control, not 
survival.7 There is a belief that venous thrombo- embolism 
is uncommon in the palliative care setting, that data 
supporting primary thromboprophylaxis are extrapolated 
from unrepresentative populations (ie, those with 
prognosis >3 months), and that outcomes from 
thromboprophylaxis studies (such as radiologically 
apparent venous thromboembolism), without consid- 
eration of symptom impact, are less relevant to people 
with advanced cancer.8,9 Venous thromboembolism in the 
SPCU setting is considered of clinical relevance only 
if it confers a patient-reported symptom burden or 
contributes to distressing symptoms at the end of life. 
Around the world, few SPCUs (whether in hospital or 
hospice settings) practice routine thromboprophylaxis.10–13 
In the UK, most hospice SPCUs are independent from 
the National Health Service and therefore lie outside 
national patient safety initiatives.14
The provision of thromboprophylaxis for patients 
receiving palliative care might therefore be determined 
by place of admission rather than clinical risk. It is 
unknown whether current practice represents over-
treatment (hospital) or under-treatment (SPCU), with 
hospital patients exposed to the risks of anticoagulation 
when none is needed, or SPCU patients exposed to the 
risks of symptomatic venous thromboembolism. We 
therefore aimed to evaluate the true prevalence of 
proximal deep vein thrombosis, diagnosed by systematic 
venous compression ultrasound, in people with 
advanced, incurable cancer admitted to an SPCU. 
Secondary outcomes included incidence during 
admission, associated factors (thromboprophylaxis), and 
clinical outcomes (symptoms or signs of venous 
thromboembolism and survival).
Methods
Study design and participants
We did a prospective, multicentre, longitudinal, ob- 
servational prevalence study. Participants were enrolled 
between June 20, 2016, and Oct 16, 2017. Institutional and 
Research in context
Evidence before this study
We searched PubMed for international and national clinical 
guidelines for the prevention of venous thromboembolism in 
patients with cancer published between Jan 1, 1980, and 
Dec 31, 2017, with no language restrictions. Excluding updates, 
of nine published clinical guidelines (one international and 
eight national), only one specifically addressed patients 
receiving palliative care with guidance based on level 5 evidence 
(grade D recommendation). The UK guideline (National 
Institute for Health and Clinical Excellence, clinical guideline 
CG92) is recommended consideration of thromboprophylaxis 
for potentially reversible causes of increased risk of venous 
thromboembolism unless the patient was in palliative care. 
We then searched PubMed for studies published in English 
between the same dates, with the terms “venous 
thromboembolism” AND “thromboprophylaxis” or 
“prophylactic” AND “palliative” OR “advanced cancer” AND 
“hospice” OR “inpatient”. We identified one randomised 
controlled trial comparing thromboprophylaxis with the 
low-molecular-weight heparin (LMWH) nadroparin versus no 
thromboprophylaxis in patients with advanced cancer in a 
specialist palliative care unit, but the study recruited only 
20 patients. Three clinician surveys identified an inconsistent 
approach to thromboprophylaxis in specialist palliative care 
units (SPCUs) and showed that in the acute setting, people with 
advanced disease are managed differently according to clinical 
specialty.Before our study, the true prevalence of clinically 
relevant deep vein thrombosis and its natural history in 
patients with advanced cancer were unknown.
Added value of this study
Our findings showed that approximately one in three people 
with advanced incurable disease admitted to an SPCU had a 
femoral deep vein thrombosis, but the he incidence of new 
thrombosis during the 3 week follow-up was low. 
Previous venous thromboembolism and being bedbound 
in the previous 3 months independently predicted deep vein 
thrombosis. We found no statistically significant association 
between deep vein thrombosis on admission and survival. 
Leg oedema was the only venous thromboembolism-relevant 
sign or symptom associated with deep vein thrombosis. 
Serum albumin concentration or use of thromboprophylaxis 
were not related to presence of deep vein thrombosis.
Implications of all the available evidence
The high prevalence but low 2-week incidence of femoral deep 
vein thrombosis in people with advanced cancer on SPCU 
admission suggests thromboprophylaxis at this stage might be 
too late. The absence of observed association with survival, or 
symptoms or signs other than leg oedema questions whether 
thromboprophylaxis offers clinically meaningful benefit. 
Our data challenge current international thromboprophylaxis 
guidelines on a number of counts. First, the findings suggest 
that the hospital model of care in which patients are risk 
assessed and given prophylaxis upon admission might be 
inappropriate for those with advanced cancer and a poor 
performance status before admission. Second, they raise 
questions about the optimal timing for introduction of 
thromboprophylaxis; should it be earlier in advanced disease? 
Recent work has shown no survival benefit with LMWH 
prophylaxis in newly diagnosed lung cancer or high-dose 
LMWH prophylaxis in pancreatic cancer, although high-dose 
LMWH prophylaxis prevented fatal pulmonary emboli. Third, is 
thromboprophylaxis of any clinical benefit at all in advanced 
disease? Is venous thromboembolism merely another 
manifestation of the inflammatory state of advanced disease, 
known to be associated with worse survival, and which does 
the greater damage at this stage of disease?
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ethical (Yorkshire and the Humber–Leeds West Research 
Ethics Committee) approvals, including for method of 
consent and management of ultrasound scan results, 
were granted before recruitment. This study is reported 
in accordance with the Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) 
statement. The protocol allowed inclusion of people with 
advanced non-malignant disease as an exploratory 
substudy. We report the cancer objectives here only; data 
relating to people with non-malignant disease are available 
elsewhere.
Eligible patients were consecutive adults with cancer, 
aged 18 years or older, admitted to one of five SPCUs 
((four hospices and one palliative care unit) in England 
(n=1), Wales (n=1), and Northern Ireland (n=3; appendix), 
who were able to give fully informed written consent or, 
in the absence of mental capacity to provide consent, an 
appropriate consultee to provide written agreement, and 
had no physical impediment to femoral vein ultrasound 
examination (eg, fixed flexion of the hip). There was no 
upper age limit to participation. If consultee agreement 
was used, retrospective consent for use of collected data 
was sought if the participant regained capacity. Patients 
with a clinician-estimated prognosis of 5 days or 
less, insufficient mental capacity and no appropriate 
consultee, or insufficient English or Welsh to provide 
consent or to comply with study assessments were 
excluded.
Eligible patients were invited to participate by the 
admitting clinician. Participants had baseline assessments 
performed by a research nurse within 48 h of admission 
including participant demographics, clinical characteristics, 
venous thromboembolism history, Wells’ score,15 and blood 
tests available from routine care. Study assessments were 
done at baseline and then weekly until discharge or death 
for a maximum of 3 weeks.
Procedures
Study outcome measures at baseline were bedside 
femoral and popliteal vein assessment by ultrasound; 
Australian-modified Karnofsky performance status 
(AKPS) score;16 clinical examination for signs or 
symptoms of venous thromboembolism (and new or 
worsening signs or symptoms at follow-up); known 
(previously confirmed) venous thromboembolism; 
bleeding; and medication record including anti- 
coagulation. Noted signs and symptoms of venous 
thromboembolism were leg oedema and prominent 
veins; tenderness along the distribution of the deep 
venous system; calf swelling (circumference at least 3 cm 
greater than the other calf, measured 10 cm below tibial 
tuberosity); and pleuritic chest pain or breathlessness. 
Bleeding was categorised as major or clinically relevant 
non-major.17 Participants were considered at high risk of 
bleeding if they had thrombo- cytopenia (platelets 
<50 × 10⁹ per L), international normalised ratio greater 
than 1·3, known active gastric or duodenal ulcer, 
known cerebral metastases, severe and uncontrolled 
hypertension, renal impairment (creatinine clearance 
<20 mL/min), or severe liver impairment.
All measures were repeated weekly apart from the 
medication record. New or worsening clinical symptoms 
and signs were reported to the clinical team. Overall 
survival was measured using routinely collected clinical 
record data from date of study enrolment until date of 
death from any cause. Deaths recorded using routinely 
collected clinical record data until 6 weeks after the end 
of recruitment.
Bilateral femoral and popliteal vein ultrasound scans 
were undertaken at the bedside by one of five trained 
research nurses, who was independent to the participant’s 
clinical care. Training occurred at a 2-day ultrasonography 
course approvied by the Royal College of Physicians, 
comprising basic ultrasonography physics, practical 
teaching, and hands-on experience. Staff underwent 
practical and theory assessments and were required to 
complete a portfolio of scans before sign-off. Specific to 
the study, trial nurses had a further day’s focused training 
to optimise skills. The scan process involved identification 
of the common femoral vein and a compressibility 
assessment performed at 2 cm increments to the level of 
the popliteal fossa.
Outcomes
The primary endpoint of the study was the prevalence of 
deep vein thrombosis within 48 h of SPCU admission. 
Secondary endpoints were associated symptoms 
attributable to deep vein thrombosis, 3-week incidence 
of new deep thrombosis during admission (with 
associated symptoms), clinical characteristics associated 
with the presence of deep vein throm bosis, association 
between use of anticoagulation and presence of deep 
vein throm bosis on, and during, admission to an SPCU, 
impact of deep vein throm bosis on length of stay, and 
overall survival. With respect to the primary endpoint, 
one of three possible outcomes was recorded for each 
scan: no deep vein thrombosis (vein compressible 
throughout), deep vein thrombosis (vein not com- 
pressible at any point), or unevaluable. Further training 
was provided 3 months into the study to optimise 
compression technique, improve image quality, and 
increase the number of evaluable images. We categorised 
scans done between June 20, and Sept 30, 2016, as early 
study scans and those done between Oct 1, 2016, and 
Oct 16, 2017, following the further training of study 
nurses in bedside ultrasound, as later study scans. All 
scans were digitally recorded and reviewed by the study 
radiologist (EN), who was the final arbiter of the presence 
of deep vein thrombosis or no deep vein thrombosis.
Because screening for deep vein thrombosis is not 
routinely undertaken in the SPCU, participants and 
clinicians were masked to ultrasound findings. However, 
the scan result could be given on request to the treating 
clinician if there was a clinical suspicion of deep vein 
See Online for appendix
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thrombosis and the scan had been undertaken within the 
previous 24 h.
We report the cancer objectives here only; data relating 
to people with non-malignant disease are available 
elsewhere.
Statistical analysis
The sample size calculation was based on a previous 
study showing bilateral obstruction of venous return in 
the legs in 17% of SPCU inpatients.18 Assuming bilateral 
obstruction represented more extensive thrombosis, we 
calculated that a sample size of 217 patients with cancer 
was needed to estimate the prevalence of proximal lower 
limb deep vein thrombosis (5% precision; 95% confidence 
level). Recruitment beyond the sample size for the 
primary outcome was permitted to improve precision for 
secondary outcomes.
Participant characteristics are summarised using 
descriptive analyses with mean (SD; range) or number (%), 
as appropriate. Prevalence (within 48 h of SPCU 
admission) is expressed as a percentage with associated 
95% CI. Participants with evaluable data for the baseline 
scan were included in our primary analysis, and the choice 
of the analysis population was not prespecified.
Univariable logistic regression models were performed 
to create odds ratios (ORs) and 95% CIs for the following 
risk factors: age, sex, baseline venous thromboembolism 
risk factors, use of anticoagulants, AKPS score, venous 
thromboembolism history, bleeding history, and bleeding 
risk. All these variables were entered in a multivariable 
logistic regression model using backward selection with 
a retention criterion of p value of less than 0·05. Adjusted 
ORs with 95% CIs were calculated. Missing data were 
not imputed. Participants with evaluable data for the 
baseline scan were included in these analyses. 
A Kaplan Meier curve was used to compare survival 
and prevalence of proximal lower limb deep vein 
thrombosis within 48 h after the patient’s admission to 
SPCU. A log-rank test was used to test for statistical 
significance. Participants who had not died by the end of 
survival data collection were right censored.
We did post-hoc sensitivity analyses excluding early 
scans (those done between June and September, 2016), to 
account for a technical learning curve, and excluding 
patients with previous history of deep vein thrombosis. 
Analyses were done with SPSS version 25.0. This study 
is registered with the ISRCTN registry, number 
ISRCTN97567719.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. MJJ, VLA, and FS had access to all the raw 
data in the study. EN had access to all scan images. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Between June 20, 2016, and Oct 16, 2017, 1390 patients 
were screened, of whom 343 were recruited (figure 1). 
11 participants were admitted more than once during the 
study period; only the first admission in the study period 
Figure 1: Flow diagram
DVT=deep vein thrombosis.
797 (57%) ineligible
389 likely to die within 5 days
85 physical limitations to 
perform ultrasonography
48 lacking capacity to consent 
or no proxy
22 consultee or patient too 
distressed
8 insufficient English or Welsh
245 outside of consent timeframe
44 non-cancer
188 remaining in the study at 
week 1
36 DVT (11 new DVT since 
baseline [previous scan: 
5 unable to evaluate, 
2 missing, and 4 no 
DVT])
60 no DVT
16 not evaluable
45 missing data
31 not scanned
78 remaining in the study at
       week 2
 36 DVT (11 new DVT since 
baseline [previous scan: 
5 unable to evaluate, 
2 missing, and 4 no 
DVT])
23 no DVT
7 not evaluable   
33 missing data
1 not scanned
 
31 remaining in the study at
      week 3
 4 DVT (0 new DVT since
            previous scan)
 8 no DVT
 4 not evaluable
 15 missing data
 0 not scanned
206 declined participation 
(38% of eligible patients)
343 patients scanned at baseline
92 DVT
181 no DVT
52 not evaluable
18 missing data
549 eligible
1390 patients screened
155 died or discharged
110 died or discharged
47 died or discharged
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(n=343) was used for analysis. There was no loss to 
follow-up.
The most common primary tumour site was lung 
(20%), followed by upper gastrointestinal, hepatobiliary, 
or pancreatic (18%), and colorectal (16%) cancer. Most 
participants (84%) had metastatic disease and 80% had at 
least one comorbidity (table 1). Almost a quarter (77 [22%] 
patients) had a history of venous thromboembolism 
(deep vein thrombosis, 36 [10%]; pulmonary embolism, 
55 [16%]). A quarter of participants (82 [24%]) 
were receiving low-molecular-weight heparin (LMWH) 
thromboprophylaxis (11 [4%] were on a direct oral 
anticoagulant; nine [3%] were taking warfarin) and 
ten (3%) had antithromboembolism stockings alone. 
40 (12%) participants were receiving full treatment 
doses of anticoagulation. Relevant symptoms at baseline 
included breathlessness (177 [52%] patients), leg oedema 
(left leg, 147 [43%]; right leg, 137 [40%]), leg pain (left leg, 
65 [19%]; right leg, 66 [19%]), haemoptysis (23 [7%]), and 
chest pain (65 [19%]). Wells’ deep vein thrombosis score 
was likely (≥2) in 174 (51%) participants.
Ultrasound scans were done in 343 patients on 
admission. According to the radiologist’s assessment, 
92 (27%) scans showed deep vein thrombosis and 
181 (53%) showed no deep vein thrombosis. 52 (15%) 
scans were not evaluable, and 18 (5%) were missing. Of 
273 patients with evaluable scans and available data, 
92 (34%, 95% CI 28–40) had femoral vein thrombosis.
Of the 273 patients with evaluable scans, 28 had a 
previous history of deep vein thrombosis (data missing 
for one patient).
Of the 343 patients with cancer, 290 had at least one 
follow-up scan with a definitive evaluation; 41 of these 
scans were unevaluable and 12 were done, but the data 
were missing. Four participants with a scan showing 
no deep vein thrombosis on admission had a deep 
vein thrombosis identified subsequently during 
their admission (maximum 3-weeks’ follow-up, figure 1). 
A further eight participants with unknown deep vein 
thrombosis status at baseline (because of missing or 
unevaluable scans) had a deep vein thrombosis.
Table 2 shows the univariable and multivariable 
regression analyses. Previous venous thromboembolism, 
being bedbound in the past 12 weeks, and lower limb 
oedema independently predicted the presence of deep 
vein thrombosis in the final multivariable model. We 
noted no association between the use of thrombo- 
prophylaxis and the presence of deep vein thrombosis on 
admission. We found no association between serum 
albumin concentration and the presence of deep vein 
thrombosis (mean serum albumin concentration 
31·4 mmol/L [SD 6·6] in patients with deep vein 
thrombosis vs 30·6 mmol/L [5·7] in patients without 
deep vein thrombosis; OR 0·98, 95% CI 0·93–1·03; 
p=0·43). Mean average survival was 30·55 days (SD 
5·65) for patients with deep vein thrombosis versus 
31·38 days (6·56) for those without deep vein thrombosis 
(p=0·432). The presence of deep vein thrombosis on 
admission was not related to survival (hazard ratio [HR] 
1·102 (95% CI 0·842–1·441; p=0·45; figure 2).
The presence of leg oedema (either leg) was an 
independent predictor of deep vein thrombosis (table 2). 
When analysed by left leg and left leg deep vein 
thrombosis (table 3), and right leg and right leg deep vein 
Total population 
(n=343)
Age (years) 68·2 (12·8; 25–102)
Sex
Male 179 (52%)
Female 164 (48%)
Family history of venous thromboembolism
Yes 49 (14%)
No or unknown 294 (86%)
Primary cancer
Lung 70 (20%)
Upper gastrointestinal, hepatobiliary, or 
pancreatic
61 (18%)
Colorectal 55 (16%)
Prostate 28 (8%)
Breast 26 (8%)
Gynaecological 25 (7%)
Head and neck 22 (6%)
Urological 19 (6%)
Unknown primary 16 (5%)
Haematological 10 (3%)
Brain 6 (2%)
Skin 3 (1%)
Bone 2 (1%)
Metastatic disease
None 56 (16%)
Yes 287 (84%)
Number of sites of metastases
1 98 (28%)
2 92 (27%)
3 65 (19%)
4 23 (7%)
5 7 (2%)
6 2 (1%)
Comorbidities
None 67 (20%)
Cardiovascular 141 (41%)
Gastrointestinal or hepatorenal 90 (27%)
Respiratory 69 (20%)
Neurological 48 (14%)
Diabetes 45 (13%)
Musculoskeletal 45 (13%)
AKPS score 49 (16·6, 20–90)
Data are mean (SD; range) or n (%). AKPS=Australian-modified Karnofsky 
performance status.
Table 1: Baseline characteristics
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No deep vein 
thrombosis (n=181)
Deep vein 
thrombosis (n=92)
Univariable analysis Multivariable analysis
Odds ratio 
(95% CI)
p value Odds ratio 
(95% CI)
p value
Demographic
Age (years) 68·4 (12·8; 25–102) 68·1 (13·5; 29–95) 0·99 (0·98–1·02) 0·86 ·· ··
Sex
Male 95/181 (52%) 50/92 (54%) 1·08 (0·65–1·78) 0·77 ·· ··
Female 86/181 (48%) 42/92 (46%) 1 (ref) ·· ·· ··
Smoking history
Current smoker 25/181 (14%) 15/92 (16%) 1·24 (0·58–2·64) 0·85 ·· ··
Ex-smoker 86/181 (48%) 43/92 (47%) 1·03 (0·59–1·78) ·· ·· ··
Never smoked 70/181 (39%) 34/92 (37%) 1 (ref) ·· ·· ··
AKPS score 50·0 (15·8; 20–90) 45·2 (16·7; 20–90) 0·98 (0·97–0·99) 0·022 ·· ··
Medical history
Family history of venous thromboembolism
Yes 22/178 (12%) 13/89 (15%) 1·21 (0·58–2·54) 0·61 ·· ··
No 156/178 (88%) 76/89 (85%) 1 (ref) ·· ·· ··
Previous pulmonary embolus
Yes 30/181 (17%) 15/92 (16%) 0·98 (0·50–1·93) 0·96 ·· ··
No 151/181 (83%) 77/92 (84%) 1 (ref) ·· ·· ··
Previous deep vein thrombosis
Yes 12/181 (7%) 16/91 (18%) 3·00 (1·36–6·66) 0·007 3·00 (1·28–7·00) 0·011
No 169/181 (93%) 75/91 (82%) 1 (ref) ·· 1 (ref) ··
Previous arterial thrombosis
Yes 6/181 (3%) 3/91 (3%) 0·99 (0·24–4·07) 0·99 ·· ··
No 175/181 (97%) 88/91 (97%) 1 (ref) ·· ·· ··
Previous venous thromboembolism
Yes 33/181 (18%) 29/92 (32%) 2·06 (1·16–3·69) 0·014 2·06 (1·16–3·69) 0·014
No 148/181 (82%) 63/92 (68%) 1 (ref) ·· 1 (ref) ··
Deep vein thrombosis risk factors within past 12 weeks
Acute medical illness
Yes 54/181 (30%) 40/92 (43%) 1·81 (1·08–3·05) 0·026 ·· ··
No 127/181 (70%) 52/92 (57%) 1 (ref) ·· ·· ··
Surgery
Yes 16/181 (9%) 10/92 (11%) 1·26 (0·55–2·89) 0·59 ·· ··
No 165/181 (91%) 82/92 (89%) 1 (ref) ·· ·· ··
Bedbound in past 12 weeks
Yes 27/181 (15%) 27/92 (29%) 2·37 (1·29–4·35) 0·005 2·66 (1·38–5·10) 0·003
No 154/181 (85%) 65/92 (71%) 1 (ref) ·· 1 (ref) ··
Bleeding within past 6 months
Major
Yes 7/181 (4%) 2/92 (2%) 0·55 (0·11–2·71) 0·46 ·· ··
No 174/181 (96%) 90/92 (98%) 1 (ref) ·· ·· ··
Non-major
Yes 15/181 (8%) 4/92 (4%) 0·50 (0·16–1·56) 0·23 ·· ··
No 166/181 (92%) 88/92 (96%) 1 (ref) ·· ·· ··
Any
Yes 22/181 (12%) 6/92 (7%) 0·50 (0·20–1·30) 0·15 ·· ··
No 159/181 (88%) 86/92 (93%) 1 (ref) ·· ·· ··
High risk of bleeding
Yes 33/181 (18%) 19/92 (21%) 1·17 (0·62–2·19) 0·63 ·· ··
No 148/181 (82%) 73/92 (79%) 1 (ref) ·· ·· ··
(Table 2 continues on next page)
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thrombosis (table 4), only left leg oedema was associated 
with the presence of ipsilateral deep vein thrombosis. 
There was no association between left leg pain and left 
leg deep vein thrombosis, or for right leg pain and right 
leg deep vein thrombosis.
At week 1, there were 188 remaining participants of 
whom seven (4%) reported new lower limb oedema, 
two (1%) reported new breathlessness, and three (2%) 
reported new chest pain. Data were missing for 15 (7%). At 
week 2 there were 80 remaining participants of whom 
one (1%) reported new lower limb pain, and none reported 
new breathlessness or new chest pain. Data were missing 
for four (5%). At week 3 (n=31) one had new leg oedema 
and one had new breathlessness. In those with an 
evaluable scan at week 1 (n=96) and week 2 (n=35), there 
was no difference in new venous thromboembolism-
attributable symptoms between those with and those 
without a deep vein thrombosis (at week 1, two [2%] 
oedema, two [2%] leg pain, zero breathlessness, and 
one [1%] chest pain in patients with deep vein thrombosis 
vs one [1%] oedema, three [5%] leg pain, zero 
breathlessness, and two [2%] chest pain in patients without 
deep vein thrombosis; at week 2, one [3%] oedema, zero 
leg pain, zero breathlessness, and zero chest pain in 
patients with deep vein thrombosis vs two [2%] oedema, 
zero leg pain, zero breathlessness, and zero chest pain in 
patients without deep vein thrombosis.
No deep vein 
thrombosis (n=181)
Deep vein 
thrombosis (n=92)
Univariable analysis Multivariable analysis
Odds ratio 
(95% CI)
p value Odds ratio 
(95% CI)
p value
(Continued from previous page)
Venous thromboembolism signs and symptoms at baseline
Lower limb oedema (either)
Yes 64/180 (36%) 49/92 (53%) 2·07 (1·24–3·44) 0·005 2·08 (1·20–3·60) 0·009
No 116/180 (64%) 43/92 (47%) 1 (ref) ·· 1 (ref) ··
Lower limb pain
Yes 33/180 (18%) 23/92 (25%) 1·48 (0·81–2·71) 0·20 ·· ··
No 147/180 (82%) 69/92 (75%) 1 (ref) ·· ·· ··
Chest pain
Yes 36/180 (20%) 15/92 (16%) 0·75 (0·39–1·47) 0·41 ·· ··
No 144/180 (80%) 77/92 (84%) 1 (ref) ·· ·· ··
Breathlessness
Yes 96/180 (53%) 45/92 (49%) 0·87 (0·52–1·43) 0·57 ·· ··
No 84/180 (47%) 47/92 (51%) 1 (ref) ·· ·· ··
Haemoptysis
Yes 13/172 (8%) 4/90 (4%) 0·53 (0·17–1·65) 0·27 ·· ··
No 159/172 (92%) 86/90 (96%) 1 (ref) ·· ·· ··
Thromboprophylaxis
Anticoagulation
Yes 43/165 (26%) 26/75 (35%) 1·51 (0·84–2·71) 0·17 ·· ··
No 122/165 (74%) 49/75 (65%) 1 (ref) ·· ·· ··
Antithromboembolism stockings
Yes 6/169 (4%) 1/80 (1%) 0·34 (0·04–2·91) 0·32 ·· ··
No 163/169 (96%) 79/80 (99%) 1 (ref) ·· ·· ··
Data are mean (SD; range) or n/N (%), unless otherwise stated. AKPS=Australian-modified Karnofsky performance status.
Table 2: Univariable and multivariable logistic regression analysis
Figure 2: Overall survival in patients with and without deep vein thrombosis on admission
Shaded areas represent 95% CIs. HR=hazard ratio.
Number at risk
(number censored)
No deep vein thrombosis
Deep vein thrombosis
0
181
89
(136)
(79)
100
16
5
(13)
(5)
200
3
1
(1)
(0)
300
2
1
(2)
(0)
400
0
0
Time (days)
0
25
50
75
100
O
ve
ra
ll 
su
rv
iv
al
 (%
)
p=0·45
HR=1·102 (95% CI 0·842–1·441)
No deep vein thrombosis
Deep vein thrombosis
Articles
e86 www.thelancet.com/haematology   Vol 6   February 2019
There were too many missing dates of SPCU discharge 
to give an estimate on length of stay.
Of 68 early study scans (done between June 2016 and 
September 2016), 28 (41%) indicated a deep vein 
thrombosis, 13 (19%) no deep vein thrombosis, 21 (31%) 
could not be evaluated, and six (9%) were missing. Of 
275 later study scans (done between October, 2016, and 
October, 2017), 64 (23%) indicated a deep vein thrombosis, 
168 (61%) no deep vein thrombosis, 31 (11%) could not be 
evaluated, and 12 (4%) were missing. The difference 
between early and later study scans for detection of deep 
vein thrombosis was strongly significant (p<0·001), 
suggesting a learning curve for scanning. We therefore did 
a post-hoc sensitivity analysis that excluded the early scans. 
Of 232 later study scans with a definitive evaluation, 
64 (28%, 95% CI 22–34) showed femoral deep vein 
thrombosis.
In a further sensitivity analysis excluding patients with a 
past history of deep vein thrombosis (n=28), 75 of 
244 patients (31%, 95% CI 25–37) had a femoral vein 
thrombosis. If early scans in this group were excluded, 
52 of 209 patients (25%, 19–31) had a femoral vein 
thrombosis.
Discussion
In this prospective longitudinal observational study, 
bedside compression ultrasonography identified femoral 
deep vein thrombosis in about a third of eligible people 
with advanced cancer admitted to an SPCU, with post-
hoc analyses suggesting apparently new diagnoses of 
deep vein thrombosis (ie, in patients with no history of 
deep vein thrombosis, using optimised scanning 
technique) in a quarter of patients. Although iliofemoral 
deep vein thrombosis indicates a large clot burden, our 
findings showed no difference in relevant symptoms 
between participants with or without deep vein 
thrombosis apart from an association with lower limb 
oedema. Participants with deep vein thrombosis were 
more likely to have a history of venous thromboembolism, 
or to have been bedbound for any reason during the 
previous 3 months, than were those without deep vein 
thrombosis. Notably, there was no association between 
the presence or absence of deep vein thrombosis and 
thromboprophylaxis use. No statistical association was 
seen between the presence of deep vein thrombosis and 
serum albumin concentration, despite previous studies 
suggesting such an association.19 However, the previous 
data were recorded in a much healthier population 
followed up for a mean 723 days. Our findings show no 
difference in survival between patients with or without 
deep vein thrombosis. The numbers of participants 
developing new deep vein thrombosis subsequent to 
admission was low and conferred no additional symptom 
burden, although these findings should be treated with 
caution in view of the small numbers of patients.
More than half of all screened patients were ineligible 
(61%), mainly because death was expected within 5 days. 
Of the 549 eligible patients, 206 (38%) declined 
participation. Ethical approval did not permit the 
recording of demographics of non-consenting patients, 
although trial nurses reported that the population was 
similar to patients who consented. However, enrolled 
participants had similar demographics to those reported 
in the National Council for Palliative Care Minimum 
Data Set for SPC inpatient units with respect to sex, age, 
primary diagnosis, and metastatic burden.
Apart from limb oedema, our findings showed no effect 
of femoral vein thrombosis on experience of venous 
thromboembolism-related symptoms, and no effect of 
thrombo- prophylaxis on deep vein thrombosis risk. 
Thrombo- prophylaxis might therefore confer no benefit 
over analgesia or other appropriate control measures for 
deep vein thrombosis symptoms in patients with cancer 
admitted to an SPCU. Recruited participants had a mean 
AKPS score of 49 (a value of 50 represents the need for 
considerable assistance and frequent medical care),16 most 
had metastatic disease and at least one comorbidity, and 
mean length of survival was only 44 days. These 
characteristics not only demonstrate a functionally 
dependent population with advanced stage of illness but 
also one previously unrepresented in thromboprophylaxis 
studies, in which life expectancy of less than 3 months was 
invariably an exclusion criterion.
This was a pragmatic multicentre study done in SPCUs 
across the UK, with broad entry criteria. Clinical studies in 
this environment are notoriously challenging, yet HIDDen 
completed target recruitment ahead of time, allowing 
analysis of adequately powered data. Unlike previous 
venous thromboembolism studies, which have been 
difficult to contextualise in advanced cancer, we used 
No left leg deep vein 
thrombosis (n=255)
Left leg deep vein 
thrombosis (n=66)
Odds ratio 
(95% CI)
p value
Left leg oedema
Yes 102 (40%) 35 (53%) 1·92 (1·07–3·43) 0·027
No 153 (60%) 31 (47%) 1 (ref) ··
Left leg pain
Yes 43 (17%) 16 (24%) 0·98 (0·48–2·01) 0·96
No 212 (83%) 50 (76%) 1 (ref) ··
Table 3: Patient-reported left leg venous thromboembolism signs and symptoms by deep vein 
thrombosis on admission
No right deep vein 
thrombosis (n=260)
Right leg deep vein 
thrombosis (n=61)
Odds ratio 
(95% CI)
p value
Right leg oedema
Yes 95 (37%) 32 (52%) 1·17 (10·67–2·07) 0·57
No 165 (63%) 29 (48%) 1 (ref) ··
Right leg pain
Yes 48 (18%) 13 (21%) 0·72 (0·33–1·53) 0·39
No 212 (82%) 48 (79%) 1 (ref) ··
Table 4: Patient-reported right leg venous thromboembolism signs and symptoms by deep vein 
thrombosis on admission
For the National Council for 
Palliative Care Minimum Data 
Set see https://www.ncpc.org.
uk/sites/default/files/user/
documents/MDS%20
Summary%20final%20
report%2014_15_0.pdf
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pre-agreed outcome measures of relevance to patients and 
treating clinicians.8 To optimise recruitment, compression 
ultrasonography was done at the bedside by trained 
research nurses and independently validated by a 
consultant radiologist. Every effort was made to ensure the 
quality of scans and for this reason additional training was 
provided to the research nurses at month 3 of the study. 
Specifically, focus was placed on improved compression 
technique and increased number of images recorded for 
radiologist review. Furthermore, we did a sensitivity 
analysis excluding the first 3 months’ scans to allow for a 
learning curve. However, we acknowledge that these 
results are likely to under-represent the prevalence of 
venous thromboembolism because the analysis will have 
omitted distal deep vein thrombosis and pulmonary 
embolus. In patients with cancer, distal deep vein 
thrombosis is associated with an increased risk of residual 
vein thrombosis, an established risk factor for recurrent 
deep vein thrombosis.20 Furthermore, identification of 
fresh deep vein thrombosis by compression ultra- 
sonography in the presence of a recent deep vein 
thrombosis is notoriously challenging and it is for this 
reason that we omitted patients with history of deep vein 
thrombosis (proximal or distal) in our additional sensitivity 
analysis.21 Additionally, 5% of scans were missing. These 
were unlikely to be missing completely at random because 
participants, although they consented to participate, might 
then have declined a scan if they felt less well. This missing 
group might therefore have included at least some patients 
more likely to have a deep vein thrombosis because of 
poorer performance status, and thus the prevalence might 
be underestimated. This issue is greater for development 
of deep vein thrombosis during follow-up, where missing 
or unevaluable scans are greater. However, data were more 
complete for symptom report, and there were no between-
group differences in new symptoms that could be 
attributable to thromboembolism.
The study sample size was calculated to provide 
adequate power for estimates of prevalence and not for 
survival, and the data are observational. A randomised 
controlled trial of thromboprophylaxis with survival as 
the primary endpoint, using data from an epidemiological 
model of venous thromboembolism-related hospital-
acquired deaths, would need a sample size of 72 000— 
unlikely to be feasible or to provide value for information 
in this patient population.22
Our data challenge current recommendations for 
prevention of venous thromboembolism prevention 
in advanced cancer.4 Strategies to prevent hospital-
acquired thrombosis remain a global health priority and 
patients with advanced cancer would seem an ideal 
patient group to target because they are highly thrombotic 
and 88% will have an average of five hospital admissions 
in their last year of life.23 A prospective observational 
study of 22 SPCUs in France identified a 9·8% (95% CI 
8·3–11·6) incidence of clinically relevant bleeding in 
1199 patients with cancer.24 Multivariate analysis 
suggested an association between clinically relevant 
bleeding and pharmacological thromboprophylaxis 
(HR 1·48, 95% CI 1·02–2·15; p=0·04).24 It would seem 
expedient to minimise the risk of harm by avoiding the 
use of thromboprophylaxis unless there will be a clear 
net benefit. Our data show a high prevalence of femoral 
deep vein thrombosis at the point of admission to the 
SPCU, making the issue of thromboprophylaxis a moot 
point. Since our data suggest these deep vein thromboses 
confer a minimal symptom burden with no evidence that 
they shorten life, rethinking the utility of pharmacological 
thromboprophylaxis in this population would seem 
reasonable. However, use of thromboprophylaxis is 
dependent upon place of admission, and is much less 
likely in SPCU inpatients than in those admitted to an 
acute hospital setting.
Whether these data can be extrapolated to the acute 
setting is debatable. The advanced cancer population in 
this study were defined by SPCU admission. The factors 
influencing the clinical decision to admit to the SPCU 
setting are unknown but will be more complex than extent 
of disease or prognosis, and are likely to include patient 
preferences, performance status, and clinician judgment 
regarding potential reversibility of any deterioration. 
Qualitative research offers some explanation for discrepant 
practice between hospitals and SPCUs. First, although 
around half of people admitted to SPCUs have evidence of 
obstruction to lower limb venous flow measured by light 
reflection rheography (17% bilateral)18 and 50% have 
venous thromboembolism at post mortem, palliative care 
teams perceive that venous thrombo embolism is not a 
common clinical problem.9 Clinicians might misattribute 
symptoms to other pathologies such as lymphoedema, 
hypoalbuminaemia, or cellulitis (for deep vein thrombosis), 
and anaemia, pneumonia, pleural effusion, heart failure, 
lymphangitis, and lung metastases (for pulmonary 
embolism). Conversely, perhaps despite a high prevalence, 
venous thromboembolism-related symptoms contribute a 
small proportion to the overall symptom burden of people 
with advanced incurable illness. In our study, a significant 
predictor for deep vein thrombosis was being bedbound 
for any reason within the past 12 weeks. This characteristic 
not only delineates a subpopulation of people with 
advanced disease with a potentially poorer prognosis, but 
also suggests that their thrombotic insult might have been 
experienced before admission as part of an inevitable 
decline rather than the cause of it. This suggestion raises 
the question whether thromboprophylaxis should be 
started before developing advanced disease. However, 
LMWH prophylaxis in patients with newly diagnosed lung 
cancer25 or high-dose LMWH prophylaxis in patients with 
pancreatic cancer26 did not improve survival, although 
high-dose LMWH prophylaxis prevented fatal pulmonary 
emboli. People with advanced cancer admitted to an acute 
hospital setting likely represent a broader population with 
respect to performance status and prognosis; therefore, 
without a clearer understanding of the demographics, we 
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cannot apply these findings beyond the SPCU setting. 
However, our study offers new insights into the utility and 
appropriateness of thromboprophylaxis strategies for 
patients with cancer nearing the end of life. The numbers 
of participants receiving anticoagulation for previously 
diagnosed deep vein thrombosis or pulmonary embolism 
were too small to draw any conclusions about any benefit 
from secondary prevention of venous thromboembolism 
for symptom control or survival.
These novel data show that approximately a third of 
patients admitted to SPCUs with advanced cancer 
and who were not expected to die within 5 days had a 
femoral deep vein thrombosis. Deep vein thrombosis was 
not associated with thromboprophylaxis, survival, or 
symptoms other than leg oedema. Findings are consistent 
with venous thromboembolism being a manifestation of 
advanced disease rather than a cause of premature death. 
Thromboprophylaxis for SPCU inpatients with poor 
performance status seems to be of little benefit.
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